CareLit · DOI-Nachweis · Pneumologie
Risk of pneumonia and exacerbations with single inhaler extrafine triple therapy compared to indacaterol/glycopyrronium: Post-hoc Analysis of the TRIBUTE Study
DOI 10.1055/s-0039-1678328
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Scuri, D Singh, LM Fabbri, A Guasconi, S Vezzoli, H Prunier, A Muraro, S Petruzzelli, A Papi
ZeitschriftPneumologie
AusgabeS 01 S 01/2019
Jahrgang / SeitenJg. 73
Kernaussage aus der Literatur
Abstract-Vorschau
Risk of pneumonia and exacerbations with single inhaler extrafine triple therapy compared to indacaterol/glycopyrronium: Post-hoc Analysis of the TRIBUTE Study
Zitieren
Zitierempfehlung
M Scuri, D Singh, LM Fabbri, A Guasconi, S Vezzoli, H Prunier, A Muraro, S Petruzzelli, A Papi (2019) Risk of pneumonia and exacerbations with single inhaler extrafine triple therapy compared to indacaterol/glycopyrronium: Post-hoc Analysis of the TRIBUTE Study. Pneumologie, 73 (S 01 S 01). https://doi.org/10.1055/s-0039-1678328
Mit CareLit weiterarbeiten